Research Current Studies and Recruitment

Current Studies

Lakeside Healthcare Research and Innovation Unit

  • Anthos Therapeutics Lilac TIMI 76 -  A study to evaluate the efficacy and safety of Abelacimab in high-risk patients with atrial fibrillation, who have been deemed unsuitable for oral anticoagulation. CONTACT US FOR MORE INFORMATION
  • AZ Bax24 - A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension. CONTACT US FOR MORE INFORMATION
  • AstraZeneca  Flash - A Phase 2a, Randomised, Double-Blind, Placebo Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma.
  • AstraZeneca  Prospero - A Phase III, Multicentre, Randomised, Double-blind, Chronic dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. 
  • AstraZeneca  Tharros - A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.
  • AstraZeneca  Titania - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. 
  • Bayer Alpine 1 - A study to learn about how well BAY3283142 works and its safety in participants with chronic kidney disease. 
  • Bellus Calm-1 - A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough. 
  • GSK Low Carbon Asthma - A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via Metered Dose Inhaler (MDI) containing propellant HFA-152a or HFA-134a in participants ≥18 years of age with asthma. 
  • Moderna CMVibe - A Phase 1/2a study for a Cytomegalovirus (CMV) Vaccine in Adult and Paediatric Participants.  
  • Moderna Fluent - A Phase 3, Randomized, Observer-blind, Active-controlled, Case driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age. 
  • Moderna Nova - A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age. 
  • MSD MK00616-015 - A Phase 3 Randomised, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk. 
  • Pfizer BHV3000-406 - A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use. 
  • Pfizer BHV3000-407 - A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications. 

To take part or find out more information about any of these studies, please contact us here for more information.

Recruitment

Lakeside Research